4.8 Article

Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling

Journal

NATURE COMMUNICATIONS
Volume 6, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms9283

Keywords

-

Funding

  1. European Research Council
  2. European 7th Framework MyoAge program
  3. Fondation de la Recherche Medicale
  4. Fondation Schlumberger pour l'Education et la Recherche
  5. European Foundation for the Study of Diabetes
  6. Institut National du Cancer (INCa)
  7. French Muscular Dystrophy Asscoiation (AFM)
  8. Agence nationale de la recherche [ANR-10-Wnt-Metaboliv]
  9. Fondation pour la Recherche Medicale
  10. National Institutes of Health, U.S.A. [GM51586]
  11. Fondation Tourre
  12. EFSD
  13. INCa
  14. EMBO
  15. French Ministry of Research
  16. ATIP-Avenir Plan Cancer Programme

Ask authors/readers for more resources

Defective hepatic insulin receptor (IR) signalling is a pathogenic manifestation of metabolic disorders including obesity and diabetes. The endo/lysosomal trafficking system may coordinate insulin action and nutrient homeostasis by endocytosis of IR and the autophagic control of intracellular nutrient levels. Here we show that class III PI3K-a master regulator of endocytosis, endosomal sorting and autophagy-provides negative feedback on hepatic insulin signalling. The ultraviolet radiation resistance-associated gene protein (UVRAG)associated class III PI3K complex interacts with IR and is stimulated by insulin treatment. Acute and chronic depletion of hepatic Vps15, the regulatory subunit of class III PI3K, increases insulin sensitivity and Akt signalling, an effect that requires functional IR. This is reflected by FoxO1-dependent transcriptional defects and blunted gluconeogenesis in Vps15 mutant cells. On depletion of Vps15, the metabolic syndrome in genetic and diet-induced models of insulin resistance and diabetes is alleviated. Thus, feedback regulation of IR trafficking and function by class III PI3K may be a therapeutic target in metabolic conditions of insulin resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available